Data on IceCure’s ProSense Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America’s 2024 Annual Meeting | PR Newswire [Video]

• ICE3 trial results presented by ICE3 Co-Principal Investigator Dr. Kenneth Tomkovich
• FDA Advisory Panel voted in favor of IceCure’s ProSense® cryoablation benefit-risk profile in early-stage low risk breast cancer in Nov. 2025
• FDA’s marketing authorization decision expected in Q1, 2025 

, /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that data from its ICE3 trial of ProSense’s® in early-stage breast cancer were presented at the Radiological Society of North America’s 2024 Annual Meeting on December 5, 2024 in Chicago, IL. The abstract titled “Cryoablation as a primary treatment for low-risk breast cancer less than 1.5 cm without surgical excision final results of the ICE3 Trial” was presented by Dr. Kenneth Tomkovich, co-principal investigator of the ICE3 trial.

Dr. Tomkovich commented, “The significance of the ICE3 results in the field of radiology, especially among breast radiologists, cannot be overstated. …